Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk in Patients Undergoing Secondary Prevention for Cardiovascular Disease.

NCT06720662 is registered in ClinicalTrials.gov with University of Sao Paulo as lead sponsor.

NCT NCT06720662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06720662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk in Patients Undergoing Secondary Prevention for Cardiovascular Disease.
Lead sponsor
University of Sao Paulo
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
January 30, 2026
Enrollment
294 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis cardiovascular disease